What is it about?
Aripiprazole and paliperidone once-monthly formulations were equally effective in reducing psychosis in patients with comorbid psychosis and substance use disorder, but aripiprazole reduced craving and improved quality of life more than paliperidone.
Featured Image
Why is it important?
In cases of comorbidity with substance use disorders, patients with psychosis fare better on craving and quality of life on aripiprazole once-monthly; hence, the latter should be preferred in such cases.
Perspectives
Aripiprazole may be compared on the above outcomes with other long-acting formulations to define whether it's a choice treatment in comorbid psychosis (schizophrenia, schizoaffective disorder, and psychotic bipolar disorder) and substance use disorder.
Dr Georgios D. Kotzalidis
Sapienza University, NESMOS Department
Read the Original
This page is a summary of: Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life, June 2018, Dove Medical Press,
DOI: 10.2147/ndt.s171002.
You can read the full text:
Contributors
The following have contributed to this page
